

Study	Vaccine	Timeframe postvaccination	Measure/s of effectiveness	Age groups included	Variants analysed	Study Type	Country	Data derived from
Tartof et. al. ⁺¹	BNT162b2 ^A	0.5 – 7.25	i) PCR positive ii) Hospitalisation ^B	12-15 16-44 45-64 ≥65	pre-Delta Delta	Retrospective cohort study	USA	Appendix tables 6-8
Goldberg et. al. ⁺²	BNT162b2 ^A	1.5-6.5 months	i) PCR positive ^C ii) Severe disease ^D	16-39 40-59 ≥60	Delta	Retrospective cohort study	Israel	Table S7
Chemaitelly et. al. ⁺³	BNT162b2	0.5-≥7 months	i) PCR positive ii) Hospitalisation (Severe disease Critical Disease And Fatal)	any	Alpha, Beta ^E , Delta	Test negative case control	Qatar	Table 2
Keehner et. al. ⁴	BNT162b2 or mRNA-1273	1-7 months	PCR positive and > 1 symptom	≥18	Delta ^F	Retrospective cohort study	USA	Calculated based on attack rates for July given in text
Andrews et. al. ⁵	BNT162b2 ChAdOx1 nCoV-19 mRNA-1273	0.5-≥9 months	i) PCR confirmed symptomatic disease ii) Hospitalisation iii) Death	≥16 ≥65 40-64 16-39	Alpha Delta	Test negative case control	England	Table 1 Table 2 Table S10 Table S11 Table S12
El Sahly et. al. ⁶	mRNA-1273	0.5-≥8 months	i) Prevention of illness ii) Prevention of severe disease	≥18-<65 ≥65	Ancestral	Randomised controlled trial	USA	Supplementary Table S30

Thomas et. al. ⁷	BNT162b2	0.25-≥4 months	i) Laboratory confirmed disease (≥ 1 symptom)	12-15 ≥16	pre-Delta	Randomised controlled trial	USA Argentina Brazil South Africa Germany Turkey	Figure 2
Rosenberg et. al. ⁸	BNT162b2 mRNA-1273	0-8 months	i) Laboratory confirmed disease ii) Hospitalisation	18-49 50-64 ≥65	pre-Delta Delta	Retrospective cohort study	USA	Tables 2 and 3
Andrews et. al. ^{9,10}	BNT162b2 ChAdOx1 nCoV-19 mRNA-1273	0.5-~25 months	i) PCR confirmed symptomatic disease ii) Hospitalisation	≥18	Delta Omicron	Test negative case control	England	Table 3
Ferdinands et. al. ¹¹	mRNA vaccines	0.5-25 months	i) PCR confirmed hospital presentation ii) PCR confirmed hospital admission	≥18	Delta Omicron	Test negative case control	USA	Table 2
Bruxvoort et. al. ^{†12}	mRNA-1273	0.5-6 months	PCR confirmed infection	≥18	Delta	Test negative case control	USA	Extracted from Figure 2
Poukka et. al. ^{†13}	mRNA vaccines ChAdOx1 nCoV-19	0-8 months	i) Laboratory confirmed infection ii) Hospitalisation	16-69	pre-Delta Delta	Retrospective cohort study	Finland	Supplementary table 2 and 3
Tseng et. al. ¹⁴	mRNA-1273	0.5-25 months	i) Infection ii) Hospitalisation	≥18	Delta Omicron	Test negative case control	USA	Table 2
Skowronski et. al. ^{†15}	BNT162b2	0.5-11.5 months	i) PCR positive infection	≥18	Delta	Test negative case control	Canada	Supplementary table 14 and 15

	ChAdOx1- nCoV-19 mRNA-1273		ii) hospitalisation					
Thompson et. al. ¹⁶	mRNA vaccines	0.5-25 months	Hospitalisation	≥18	Delta Omicron	Test negative case control	USA	Table 2

Supplementary Table 1 Data sources for Efficacy Data

^A Fully vaccinated = 7 days + post second dose

^B Hospitalisation data was not split by variant

^C PCR positive efficacy included for ages >16 years

^D Severe disease efficacy included for ages >40 years

^E Effectiveness against Beta infections were not included in this analysis

^F Infections were >95% Delta in timeframe analysed

[†] Denotes studies that included efficacy against confirmed infection without reporting on symptoms. These data were not included in the final analysis.

References:

1. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet* 2021; **398**(10309): 1407-16.
2. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. *N Engl J Med* 2021; **385**(24): e85.
3. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med* 2021; **385**(24): e83.
4. Keehner J, Horton LE, Binkin NJ, et al. Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce. *N Engl J Med* 2021; **385**(14): 1330-2.
5. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. *N Engl J Med* 2022; **386**(4): 340-50.
6. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med* 2021; **385**(19): 1774-85.
7. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med* 2021; **385**(19): 1761-73.
8. Rosenberg ES, Dorabawila V, Easton D, et al. Covid-19 Vaccine Effectiveness in New York State. *N Engl J Med* 2022; **386**(2): 116-27.
9. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med* 2022; **386**(16): 1532-46.
10. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. *medrxiv* 2021: doi:10.1101/2021.12.14.21267615.
11. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(7): 255-63.
12. Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. *BMJ* 2021; **375**: e068848.
13. Poukka E, Baum U, Palmu AA, et al. Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. *Vaccine* 2022; **40**(5): 701-5.
14. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. *Nat Med* 2022; **28**(5): 1063-71.
15. Skowronski DM, Febriani Y, Ouakki M, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. *medrxiv* 2021.
16. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(4): 139-45.